U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

2023
446
Name Type Language
VILOBELIMAB
USAN   INN  
Official Name English
IFX-1
Preferred Name English
IMMUNOGLOBULIN G4, ANTI-(HUMAN COMPLEMENT C5A) (HUMAN-MUS MUSCULUS MONOCLONAL IFX-1 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL IFX-1 .KAPPA.-CHAIN, DIMER
Systematic Name English
CACP29
Code English
vilobelimab [INN]
Common Name English
Vilobelimab [WHO-DD]
Common Name English
VILOBELIMAB [USAN]
Common Name English
CACP 29
Code English
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT 5) ANAPHYLATOXIN (C5A, C5 PR678-751)), CHIMERIC MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN CHIMERIC (1-446) (VH (MUS MUSCULUS IGHV1-61*01 (81.6%)-(IGHD)-IGHJ3*01 (92.9%)/HOMO SAPIENS IGHV1-46*01 (62.2
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 884822
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
Code System Code Type Description
USAN
HI-123
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
SMS_ID
300000021741
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
FDA UNII
F5T0RF9ZJA
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
DAILYMED
F5T0RF9ZJA
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
INN
11304
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
CAS
2250440-41-4
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
CAS
2161337-20-6
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
SUPERSEDED
NCI_THESAURUS
C172643
Created by admin on Tue Apr 01 22:51:00 GMT 2025 , Edited by admin on Tue Apr 01 22:51:00 GMT 2025
PRIMARY
ACTIVE MOIETY
VILOBELIMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966